Category Archives: Brain metastases

Loralatinib phase II results

Published on 11-6-18, I believe in conjunction with the FDA approval. 276 ALK+ & ROS1+ patients. But only adverse events were reported for the ROS1 patients The description of the results in the article I found was very confusing. The … Continue reading

Posted in Brain metastases, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Brigatinib vs Crizotinib phase 3 interim results

In September 2018, Takeda reported a pre-designated first interim analysis of a phase 3 trial in the New England Journal of Medicine. The study enrolled 275 ALK inhibitor naive patients. Half got Brigatinib and half got Crizotinib. For Brigatinib: at … Continue reading

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, crizotinib - Xalkori from Pfizer, Lung cancer, Research | Leave a comment

FDA conditionally approves Loralatinib

As of 11-2-2018 the FDA conditionally approved Loralatinib. It’s brand name is Lorbrena. The approval is for Loralatinib treatment for patients: 1) as a third line after crizotinib and one other ALK inhibitor (basically Brigatinib), or 2) as a second line treatment … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

FDA approves alectinib (Alecensa) as 1st line treatment

As of November 6, 2017 FDA approves alectinib (Alecensa) as 1st line treatment based on Phase 3 results. The estimated median Progression Free Survival (PFS) for patients taking alectinib was 25.7 months, compared with 10.4 months for those taking crizotinib. The … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Phase 1 & 2 full results for Lorlatinib

As of Oct. 16, 2017 Pfizer presented a Press release associated with a presentation at IASLC on Phase 2 results for 275 patients. All following are for ALK+ patients except where Ros1 is indicated Treatment Naive:  ORR 90%; IC-ORR 75% Prior … Continue reading

Posted in Brain metastases, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Great page with very high quality info on AlK & AlK inhibitors

Below is a link to a page that provides comprehensive regularly updated info written by two ALK research oncologists Dr. Alice Shaw and Ben Solomon, Phd (then edited by three people). It is written for an audience of doctors and … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments | Leave a comment

Roche at ASCO with Alectinib findings

Roche (Genentech) announced on June 6, 2017 at the 2017 ASCO conference that the have results from their first line Phase 3 Global Trial that Alectinib had a median PFS of 25.7 months vs 10.4 months for Crizotinib (over a … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Zykadia (ceritinib) by Novartis is approved for first line use in US

As of May 26, 2017 the FDA approved ceritinib for first line use. So it will go head to head with crizotinib. One article said a similar EU approval was likely “in coming weeks”. The results are based on the … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research | Leave a comment

Lorlatinib granted breakthrough therapy status

On April 27, 2017, the FDA granted Pfizer Breakthrough Status on lorlatinib for patients previously treated with one or more ALK inhibitors. So you don’t have to take Crizotinib first, any of the other 3 will do. Also a Phase … Continue reading

Posted in Brain metastases, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Clinical trial of TPX-0005 from TP Therapeutics

As of March 6, 2017, ClinicalTrials.gov lists a Trial of TPX-0005 which targets ALK, ROS1, and NTRK 1-3. At this time there are four trial sites at: UC Irvine Cancer center, University of Colorado, Denver, Massachusetts General Hospital, and Memorial … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, TPX-0005: TP Therapeutics | Leave a comment